Botanix is an American company that develops new prescription treatments for serious skin diseases such as acne and it recently listed on the ASX on 15 July in an oversubscribed offer which raised $3.5 million.
The management team believes Australia is the perfect place to list given the ability to fast track clinical and human trials to allow for FDA approval down the line.
